Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
Fractyl Health (Nasdaq: GUTS) reported one-year, randomized sham-controlled REMAIN-1 midpoint cohort results for its Revita DMR system after GLP-1 discontinuation. In mITT (N=45), weight regain was 7.8% vs 13.0% with sham. Complete duodenal ablation (>14 cm) retained ~81% vs 48% with sham. No device-related serious AEs. Next: six-month pivotal topline in early Q4 2026 and possible FDA De Novo late Q4 2026.
How this was made
The 30-second read
Why it matters
The disclosed one-year randomized, sham-controlled durability results (including responder and safety/tolerability details) provide a fresh efficacy datapoint that can influence expectations for the upcoming REMAIN-1 pivotal cohort topline and the potential FDA De Novo submission timeline.
Market read
New one-year randomized durability and safety data after GLP-1 discontinuation, plus explicit next milestones, create a tradable catalyst path for GUTS into Q4 2026.
What to watch
Durability claims depend on subgroup definitions (complete duodenal ablation length and GLP-1 run-in loss). Traders may discount the headline if real-world procedure completeness or patient selection differs from trial conditions.
Background
Fractyl is developing Revita, a one-time endoscopic DMR system intended to maintain weight after patients stop GLP-1 therapies; REMAIN-1 is the pivotal weight-maintenance program.
Ticker impact
Fractyl reported positive one-year REMAIN-1 midpoint results showing Revita reduced weight regain versus sham after GLP-1 discontinuation.
Near-term upside bias for GUTS on clinical-data momentum, with volatility likely into early Q4 2026 topline milestones.
The article discloses new randomized, sham-controlled one-year efficacy and safety outcomes, plus specific next catalysts (Q4 2026 six-month topline and late Q4 2026 potential De Novo submission). However, midpoint cohort is described as not powered for formal inference, which can limit magnitude of repricing.
Market effects
Supports the broader obesity-treatment procedural-device thesis, potentially improving sentiment toward non-drug weight maintenance approaches.
Primarily US-focused biotech/device sentiment; limited direct regional read-through beyond clinical trial risk appetite.
CE-marked status and FDA De Novo pathway make the US regulatory trajectory a key global reference point for similar metabolic device programs.
Counterpoint
Because the midpoint cohort is explicitly not powered for formal statistical significance, the effect size may not translate into a clear pivotal endpoint clearance, limiting how far the stock can re-rate.
Key entities
- companyFractyl Health, Inc.
Clinical-stage metabolic therapeutics company advancing Revita for post-GLP-1 weight maintenance.
- product_candidateRevita DMR System
One-time minimally invasive endoscopic procedure intended to remodel the duodenal lining for durable weight maintenance.
- clinical_programREMAIN-1 Midpoint Cohort
Randomized, double-blind, sham-controlled cohort evaluating Revita after discontinuation of tirzepatide/GLP-1 therapy.
- regulatory_pathwayFDA De Novo
Potential late Q4 2026 submission referenced as a next regulatory milestone for Revita.
